As a result, inhibiting PDE 10 A might be deemed as a promising anticancer therapeutic strategy.296 Raab et al. revealed that a new selective SIK2 small molecule inhibitor, MRIA9, could enhance the sensitivity of ovarian cancer cells and patients to paclitaxel treatment. Here, SIK2 is linked to ovarian cancer.